Related Experiment Videos
Ulcerative terminal ileitis after BCG therapy for bladder carcinoma
D Satgé1, I Pommepuy, T Hassan
1Laboratoire d'Anatomie Pathologique, Centre Hospitalier, Tulle, France. daniel.satge@ch-tulle.fr
Histopathology
|September 5, 2002
Summary
Bacillus Calmette-Guérin (BCG) therapy for bladder cancer can cause ulcerative ileitis. This rare side effect, affecting the terminal ileum, highlights potential digestive tract complications from BCG treatment.
Area of Science:
- Oncology
- Gastroenterology
- Immunology
Background:
- Bacillus Calmette-Guérin (BCG) is a common immunotherapy for bladder carcinoma.
- Ulcerative ileitis is an inflammation of the ileum characterized by ulceration.
- Gastrointestinal side effects of BCG therapy are rare but can be severe.
Observation:
- A 77-year-old patient receiving BCG therapy for bladder carcinoma presented with ulcerative ileitis.
- Standard etiological investigations excluded common causes like Crohn's disease, tuberculosis, and ischemia.
- Histological examination and clinical data pointed towards a locoregional reaction to BCG.
Findings:
- The case suggests a diagnosis of BCG ileitis affecting the terminal ileum.
- Intestinal involvement following BCG therapy is exceptionally rare.
- This observation highlights a potential gastrointestinal manifestation of BCG treatment.
Implications:
- This case expands the known spectrum of adverse reactions to BCG therapy.
- Physicians should consider BCG ileitis in patients with gastrointestinal symptoms during or after BCG treatment.
- Further research may be warranted to understand the incidence and mechanisms of BCG-induced enteritis.